1. Search Result
Search Result
Results for "

Cyclopenin

" in MedChemExpress (MCE) Product Catalog:

82

Inhibitors & Agonists

123

Peptides

20

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0031
    Cyclo(RADfK)
    1 Publications Verification

    Integrin Others
    Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.
    Cyclo(RADfK)
  • HY-P0023
    Cyclo(-RGDfK)
    Maximum Cited Publications
    14 Publications Verification

    Integrin Cancer
    Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
    Cyclo(-RGDfK)
  • HY-P0231
    AZP-531
    2 Publications Verification

    GHSR Metabolic Disease Endocrinology
    AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight.
    AZP-531
  • HY-P1934
    Cyclo(Phe-Pro)
    4 Publications Verification

    Cyclo(phenylalanylprolyl); A-64863

    HCV Infection
    Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)), a Vibrio vulnificus quorum-sensing molecule, inhibits retinoic acid-inducible gene-I (RIG-I) polyubiquitination, through its specific interaction with RIG-I, to blunt IRF-3 activation and type-I IFN production. Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) enhances susceptibility to hepatitis C virus (HCV), as well as Sendai and influenza viruses .
    Cyclo(Phe-Pro)
  • HY-126810A

    Fungal Infection
    NP213 TFA is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 TFA targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 TFA is effective and well-tolerated in resolving nail fungal infections .
    NP213 TFA
  • HY-P0023A
    Cyclo(-RGDfK) TFA
    Maximum Cited Publications
    14 Publications Verification

    Integrin Cancer
    Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
    Cyclo(-RGDfK) TFA
  • HY-113626

    (-)-Cyclopenine

    Cholinesterase (ChE) Metabolic Disease
    (-)-Cyclopenin ((-)-Cyclopenine) is the enantiomer of Cyclopenin. Cyclopenin is a selective acetylcholinesterase (AChE) inhibitor with the IC50 of 2.04 μM .
    (-)-Cyclopenin
  • HY-113626A

    (±)-IsoCyclopenine

    Cholinesterase (ChE) Neurological Disease
    Cyclopenin ((±)-Isocyclopenine) is a racemate .
    Cyclopenin
  • HY-114881

    NSC 246118

    Fungal Infection
    Frequentin, a secondary metabolite produced by Penicillium janthinellum, is influenced by environmental conditions such as cadmium nitrate and sodium chloride concentrations. In cadmium nitrate-free medium, P. janthinellum produces cyclopenin, carlosic acid, erythroskyrin, kojic acid, and patulin. At 100 ppm cadmium nitrate, it produces cyclopenin, carlosic acid, frequentin, and islandicin. In the presence of sodium chloride, frequentin is produced at 2% and 3% concentrations. These findings indicate that frequentin production is sensitive to specific environmental stressors, highlighting its potential variability under different growth conditions .
    Frequentin
  • HY-101402

    Cyclo(histidyl-proline); Histidylproline diketopiperazine

    NF-κB Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Cyclo(his-pro) (Cyclo(histidyl-proline)) is an orally active cyclic dipeptide structurally related to tyreotropin-releasing hormone . Cyclo(his-pro) could inhibit NF-κB nuclear accumulation. Cyclo(his-pro) can cross the brain-blood-barrier and affect diverse inflammatory and stress responses .
    Cyclo(his-pro)
  • HY-126810

    Fungal Infection
    NP213 is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 is effective and well-tolerated in resolving nail fungal infections .
    NP213
  • HY-107245
    Segetalin B
    1 Publications Verification

    Estrogen Receptor/ERR Metabolic Disease
    Segetalin B, a cyclopentapeptide from Vaccaria segetalis, possesses estrogen-like activity .
    Segetalin B
  • HY-P1934A

    Fungal IFNAR Reactive Oxygen Species Infection Inflammation/Immunology Cancer
    Cyclo(L-Phe-L-Pro), isolated from Pseudomonas fluorescens and Pseudomonas alcaligenes cell-free culture supernatants is an antifungal cyclic dipeptide . Cyclo(L-Phe-L-Pro) inhibits IFN-β production by interfering with retinoic-acid-inducible gene-I (RIG-I) activation . Cyclo(L-Phe-L-Pro) exhibits free-radical scavenging activity with the IC50 of 24 µM in the DPPH assay .
    Cyclo(L-Phe-L-Pro)
  • HY-P2300

    Cyclo(RGDfC)

    Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
  • HY-P1938

    Bacterial Infection
    Cyclo(L-Pro-L-Val) is a 2,5-diketopiperazine, with toxic activity against phytopathogenic microorganisms (such as R. fascians LMG 3605). Cyclo(L-Pro-L-Val) shows toxicity similar to Chloramphenicol (HY-B0239) with comparable concentration. Cyclo(L-Pro-L-Val) can also inhibit gram-positive phytopathogenic bacterium. Cyclo(L-Pro-L-Val) has potential development as biopesticide .
    Cyclo(L-Pro-L-Val)
  • HY-P5033

    Bacterial Cancer
    Cyclo(Gly-His) is a liposome-encapsulated cyclic dipeptide with antimicrobial and anticancer activity. Cyclo(Gly-His) has cytotoxicity for HeLa and MCF-7 cell with IC50 values of 1.699 mM and 0.358 mM, respectively. Cyclo(Gly-His) can be used for the research of drug delivery systems .
    Cyclo(Gly-His)
  • HY-P5314

    EGFR STAT Others
    OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research .
    OK2
  • HY-P1935

    Biochemical Assay Reagents Cancer
    Cyclo(Ala-Pro) is an anticancer agent that is toxic to cancer cells such as A549, HCT-116 and HepG2 .
    Cyclo(Ala-​Pro)
  • HY-P5038

    c(GRGDSP)

    Integrin Cancer
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide. Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) is a synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin expressed on Caco-2 cells .
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro)
  • HY-P5698

    Bacterial Infection
    Cyclopetide 1 (Compound 1) is an antimicrobial peptide with moderate activity against B. subtilis, with a MIC of 25 μg/mL .
    Cyclopetide 1
  • HY-P5699

    Bacterial Infection
    Cyclopetide 2 (Compound 2) is an antimicrobial peptide with moderate activity against B. subtilis, with a MIC of 50 μg/mL .
    Cyclopetide 2
  • HY-P10052

    VEGFR Cancer
    CBO-P11 specifically binds to receptor of VEGFR-2 and is used as targeting ligand for tumor angiogenesis. CBO-P11 is modified with a nearinfrared cyanine dye bearing an alkyne function, allowing both “click” coupling on azido-modified nanoparticles and fluorescence labelling .
    CBO-P11
  • HY-P10222

    HIF/HIF Prolyl-Hydroxylase Cancer
    Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 14.5 and 10.2 μM, respectively .
    Cyclo(CRLLIF)
  • HY-P10223

    HIF/HIF Prolyl-Hydroxylase Cancer
    Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 65 and 123 μM, respectively .
    Cyclo(CRVIIF)
  • HY-P10221A

    HIF/HIF Prolyl-Hydroxylase Cancer
    Cyclo CKLIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 2.6 and 2.2 μM, respectively .
    Cyclo(CKLIIF) TFA
  • HY-P3119

    Desotamide A

    Bacterial Infection
    Desotamide is a cyclic hexapeptide antibiotic originally isolated from Streptomyces. It is active against S. aureus, S. pneumoniae, and methicillin-resistant S. epidermidis (MRSE; MICs=16, 12.5, and 32 μg/mL, respectively).
    Desotamide
  • HY-139425

    Biochemical Assay Reagents Cancer
    Cyclo(Pro-Ala) is an anticancer agent that has toxic to cancer cells such as A549, HCT-116, and HepG2 .
    Cyclo(Pro-Ala)
  • HY-P10426

    HIF/HIF Prolyl-Hydroxylase VEGFR Cancer
    cyclo(CLLFVY) is an inhibitor for hypoxia inducible factor-1 (HIF-1), with IC50 of 19 μM (in U2OS) and 16 μM (in MCF-7). cyclo(CLLFVY) binds to the PAS-B domain of HIF-1α, inhibits HIF-1 dimerization and transcriptional activity. cyclo(CLLFVY) downregulates the expression of hypoxia response genes, such as VEGF and CAIX, exhibits antitumor against the HIF-1 associated cancers .
    cyclo(CLLFVY)
  • HY-P6294

    Tyrosinase Others
    Pseudostellarin G is a natural cyclic octapeptide. Pseudostellarin G has the activity of inhibiting tyrosinase. Pseudostellarin G can inhibit the production of melanin .
    Pseudostellarin G
  • HY-N11955

    Others Others
    Cyclo(Ile-Leu) is a Alkaloids product that can be isolated from From Penicillium oxalicum .
    Cyclo(Ile-Leu)
  • HY-P4820A

    Bacterial Inflammation/Immunology
    SYNV-cyclo(CGGYF) TFA is a Staphylococcus hominis (S. hominis) C5 autoinducing peptide. SYNV-cyclo(CGGYF) TFA inhibits S. aureus activity. SYNV-cyclo(CGGYF) TFA has the potential for the research of S. aureus-mediated epithelial damage and inflammation .
    SYNV-cyclo(CGGYF) TFA
  • HY-P4820

    Bacterial Inflammation/Immunology
    SYNV-cyclo(CGGYF) is a Staphylococcus hominis (S. hominis) C5 autoinducing peptide. SYNV-cyclo(CGGYF) inhibits S. aureus activity. SYNV-cyclo(CGGYF) has the potential for the research of S. aureus-mediated epithelial damage and inflammation .
    SYNV-cyclo(CGGYF)
  • HY-P3227

    XJ735

    Integrin Inflammation/Immunology
    Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective RGD peptide antagonist and has the potential for Pulmonary arterial hypertension Research .
    Cyclo(Ala-Arg-Gly-Asp-Mamb)
  • HY-P5712

    Gramicidin soviet

    Antibiotic Bacterial Infection
    Gramicidin S (Gramicidin soviet) is a cationic cyclic peptide antibiotic. Gramicidin S is active against Gram-negative and Gram-positive bacteria by perturbing integrity of the bacterial membranes. Gramicidin S also inhibits cytochrome bd quinol oxidase .
    Gramicidin S
  • HY-P1201

    Somatostatin Receptor Cancer
    Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .
    Cyclosomatostatin
  • HY-P1201A

    Somatostatin Receptor Cancer
    Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .
    Cyclosomatostatin TFA
  • HY-149205

    PI3K ERK Inflammation/Immunology
    CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs). CXJ-2 exhibits potent activities to inhibit the PI3K/ERK pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy .
    CXJ-2
  • HY-P5840

    Biochemical Assay Reagents Cancer
    Cyclo(RGDyC) is a cyclic pentapeptide with anti-angiogenic abilities. Cyclo(RGDyC) can be combined with liposome delivery systems for research on ocular neovascular diseases and cancer .
    Cyclo(RGDyC)
  • HY-P1613A

    Cyclo(RGDfV) TFA; C(RGDfV) TFA

    Integrin Apoptosis Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .
    Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA
  • HY-P1613

    Cyclo(RGDfV); C(RGDfV)

    Integrin Apoptosis Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .
    Cyclo(Arg-Gly-Asp-D-Phe-Val)
  • HY-P3557

    Adrenergic Receptor Cardiovascular Disease
    Mibenratide, a small cyclic peptide, is an adrenergic β1 receptor antagonist. Mibenratide can be used for heart failure research .
    Mibenratide
  • HY-P1676

    BK-1361

    MMP Cancer
    cyclo(RLsKDK) (BK-1361) is a specific inhibitor of metalloproteinase ADAM8 with an IC50 value of 182 nM. cyclo(RLsKDK) has potential applications in inflammatory diseases and cancer .
    cyclo(RLsKDK)
  • HY-P1676A

    BK-1361 TFA

    MMP Cancer
    cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of metalloproteinase ADAM8 with an IC50 value of 182 nM. cyclo(RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer .
    cyclo(RLsKDK) TFA
  • HY-P5021

    c(RGDfE)

    Biochemical Assay Reagents Cancer
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) (c(RGDfE)) is a cyclic RGD peptide that serves as a conjugated multifunctional nanodrug delivery system to target Gemcitabine to pancreatic cancer cells. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) can be used in cancer research .
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)
  • HY-P5023

    c(RADyK)

    Biochemical Assay Reagents Cancer
    Cyclo (ARG-ALA-ASP- (D-Tyr) -LYS) (C (Radyk)) is a control peptide for c(RGDyK) .
    Cyclo(Arg-Ala-Asp-(D-Tyr)-Lys)
  • HY-P3557A

    Adrenergic Receptor Cardiovascular Disease
    Mibenratide TFA, a small cyclic peptide, is an adrenergic β1 receptor antagonist. Mibenratide TFA can be used for heart failure research .
    Mibenratide TFA
  • HY-P5023A

    c(RADyK) TFA

    Biochemical Assay Reagents Cancer
    Cyclo (ARG-ALA-ASP- (D-Tyr) -LYS) (TFA) (C (Radyk) (TFA)) is a control peptide for c(RGDyK) .
    Cyclo(Arg-Ala-Asp-(D-Tyr)-Lys) TFA
  • HY-P10548

    Bacterial Infection
    Cyclic L27-11 is a cyclic peptide-like antibiotic with strong antibacterial activity against specific bacteria such as Pseudomonas sp. Cyclic L27-11 shows nanomolar antibacterial activity against Pseudomonas sp., especially Pseudomonas aeruginosa. Cyclic L27-11 interferes with the function of bacterial outer membrane protein LptD, preventing the normal transport of lipopolysaccharide (LPS), leading to the accumulation of membrane-like substances in bacterial cells, which in turn affects the survival of bacteria. Cyclic L27-11 can be used in the development of antibacterial agents .
    Cyclic L27-11
  • HY-P5907

    Opioid Receptor Neurological Disease
    Helianorphin-19 is a potent and selective κ-opioid receptor (KOR) activator with a Ki of 21 nM and an EC50 of 45 nM. Helianorphin-19 exhibits strong KOR-specific peripheral analgesic activity in a mouse model of chronic visceral pain .
    Helianorphin-19
  • HY-12378
    BQ-123
    2 Publications Verification

    Endothelin Receptor Cardiovascular Disease
    BQ-123 is a potent and selective endothelin A (ETA) receptor antagonist with an IC50 of 7.3 nM and a Ki of 25 nM. BQ-123 inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells and lowers blood pressure in different rat models of hypertension .
    BQ-123

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: